ClinicalTrials.gg
CompletedNCT00790192PEARL 3Updated Mar 17, 2016Results posted

Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

A Phase 3 interventional study of Lurasidone and Lurasidone in Schizophrenia, sponsored by Sumitomo Pharma America, Inc.. Completed at 65 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-03-17.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
488
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
5th of 39
488 · median 149
Started
2008
with 8 others
Phase 3
18 of 39
none open now
Registered
9th of 39
by date
Lead sponsor
23 of 39
Sumitomo Pharma America, Inc.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 5th largest by enrollment, is one of 9 that started in 2008, is one of 18 in phase 3, and was the 9th registered.

Schizophrenia

3,567 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR short term among acutely psychotic patients with chronic schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • SM-13496
  • Latuda
  • Lurasidone
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written and aged between 18 and 75 years of age.
  • Meets ™ criteria for a primary diagnosis of schizophrenia.
  • Not pregnant, if of agrees to remain abstinent or use adequate and reliable for duration of study.
  • Able and agrees to remain off prior antipsychotic medication for the duration of study.
  • Good physical health on the basis of medical history, physical examination, and laboratory screening.
  • Willing and able to comply with the protocol, including the inpatient requirements and outpatient visits.

Exclusion criteria

Exclusion Criteria:

  • Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.
  • Any chronic organic disease of the CNS (other than schizophrenia).
  • Used compound within 30 days.
  • or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
488 participants (actual)

Study arms

  • Experimental
    Lurasidone 80mg

    Drug: Lurasidone

  • Experimental
    Lurasidone 160mg

    Drug: Lurasidone

  • Active comparator
    Quetiapine XR

    Drug: Quetiapine XR

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Lurasidone 80 mg tablets

  • Lurasidone 4 40 mg tablets

  • Quetiapine XR 600mg

  • DrugPlacebo

    Matching Placebo to Lurasidone or Quetiapine

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Endpoint: Mean Change in Total PANSS Score From Baseline to the End of the Double Blind Phase

    The PANSS (Positive and Negative Syndrome Scale) is a 30-item scale (range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.

    Time frame: Week 6

Secondary outcomes

  1. Secondary Outcome: CGI-S From Baseline to the End of the Double-blind Treatment

    Clinical Global Impression of Severity is a clinician-rated assessment of the subject's current illness state on a 7 point scale, where a higher score is associated with greater illness severity. The scale has a single item measured on a 7 point scale from 1 ('normal', not ill) to 7 (extremely ill).

    Time frame: 6-Weeks

07

Results

Posted Oct 6, 2011

Participant flow

Participant flow — Overall Study
MilestoneLurasidone 80 mgLurasidone 160 mgQuetiapine XR 600mgPlacebo
Started125121120122
Completed89939774
Not completed36282348

Outcome measures

PrimaryPrimary Efficacy Endpoint: Mean Change in Total PANSS Score From Baseline to the End of the Double Blind Phase

The PANSS (Positive and Negative Syndrome Scale) is a 30-item scale (range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.

Time frame:
Week 6
Reported as:
Least squares mean · scores on a scale
Primary Efficacy Endpoint: Mean Change in Total PANSS Score From Baseline to the End of the Double Blind Phase
scores on a scaleLurasidone 80 mgLurasidone 160 mgQuetiapine XR 600mgPlacebo
Primary Efficacy Endpoint: Mean Change in Total PANSS Score From Baseline to the End of the Double Blind Phase-22.2 (-25.7 to -18.7)-26.5 (-30.0 to -23.0)-27.8 (-31.3 to -24.2)-10.3 (-13.9 to -6.7)
Statistical analysis
  • Lurasidone 80 mg vs Lurasidone 160 mg vs Quetiapine XR 600mg vs Placebo · Mixed Models Analysis · p = <0.05
SecondarySecondary Outcome: CGI-S From Baseline to the End of the Double-blind Treatment

Clinical Global Impression of Severity is a clinician-rated assessment of the subject's current illness state on a 7 point scale, where a higher score is associated with greater illness severity. The scale has a single item measured on a 7 point scale from 1 ('normal', not ill) to 7 (extremely ill).

Time frame:
6-Weeks
Reported as:
Least squares mean · scores on a scale
Secondary Outcome: CGI-S From Baseline to the End of the Double-blind Treatment
scores on a scaleLurasidone 80 mgLurasidone 160 mgQuetiapine XR 600mgPlacebo
Secondary Outcome: CGI-S From Baseline to the End of the Double-blind Treatment-1.5 (-1.7 to -1.3)-1.7 (-1.9 to -1.5)-1.7 (-1.9 to -1.5)-0.9 (-1.1 to -0.7)
Statistical analysis
  • Lurasidone 80 mg vs Lurasidone 160 mg vs Quetiapine XR 600mg vs Placebo · Mixed Models Analysis · p = <0.05

Adverse events

Collected over 14 days post study therapy. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone 80 mg—1/125 (0.8%)71/125 (56.8%)
Lurasidone 160 mg—4/121 (3.3%)76/121 (62.8%)
Quetiapine XR 600mg—1/119 (0.8%)70/119 (58.8%)
Placebo—4/121 (3.3%)69/121 (57%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventLurasidone 80 mgLurasidone 160 mgQuetiapine XR 600mgPlacebo
Left Ventricular DysfunctionCardiac disorders1/1254/1211/1194/121
Pyschotic DisorderPsychiatric disorders0/1250/1211/1192/121
Suicidal IdeationPsychiatric disorders0/1250/1210/1192/121
Hepatitis ViralInfections and infestations0/1250/1211/1190/121
Abdominal Hernia ObstructiveGastrointestinal disorders0/1251/1210/1190/121
Non-cardiac Chest PainGeneral disorders0/1251/1210/1190/121
Hand FractureInjury, poisoning and procedural complications0/1251/1210/1190/121
AgressionPsychiatric disorders0/1250/1210/1191/121
SchizophreniaPsychiatric disorders0/1251/1210/1190/121
Suicidal BehaviorPsychiatric disorders0/1250/1210/1191/121
Most frequent other events
Showing 10 of 16
Most frequent other events
EventLurasidone 80 mgLurasidone 160 mgQuetiapine XR 600mgPlacebo
DizzinessNervous system disorders6/1257/12116/1192/121
SomnolenceNervous system disorders5/1258/12116/1191/121
InsomniaPsychiatric disorders14/1258/1215/11911/121
HeadacheNervous system disorders12/12512/12113/11913/121
AgitationPsychiatric disorders4/1256/1213/11910/121
AnxietyPsychiatric disorders9/1254/1211/11910/121
NauseaGastrointestinal disorders10/1258/1214/1194/121
AkathisiaNervous system disorders10/1259/1212/1191/121
Dry MouthGastrointestinal disorders2/1252/1219/1191/121
VomitingGastrointestinal disorders8/1259/1216/1196/121

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lurasidone 80 mgLurasidone 160 mgQuetiapine XR 600mgPlaceboTotal
Mean36.2 ± 10.937.9 ± 11.337.4 ± 10.437.4 ± 10.837.2 ± 10.8
Gender
Gender(participants)Lurasidone 80 mgLurasidone 160 mgQuetiapine XR 600mgPlaceboTotal
Female29394244154
Male96827777332
Region of Enrollment
Region of Enrollment(participants)Lurasidone 80 mgLurasidone 160 mgQuetiapine XR 600mgPlaceboTotal
United States40373539151
Ukraine1920191775
Romania1311131249
Russian Federation2222212287
India2425252498
Colombia766726
08

Study locations

65 sites
  • K&S Professional Research Services, LLC
    Little Rock, Arkansas 72201, United States
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Clinical Pharmacological Studies, Inc.
    Cerritos, California 90703, United States
  • Comprehensive Neuroscience, Inc
    Cerritos, California 90703, United States
  • Clinical Innovations, Inc.
    Costa Mesa, California 92647, United States
  • Synergy Escondido
    Escondido, California 92025, United States
  • Collaborative Neuroscience Network
    Garden Grove, California 92645, United States
  • Apostle Clinical Trials, Inc.
    Long Beach, California 90813, United States
  • California Clinical Trials
    Paramount, California 90723, United States
  • Pasadena Research Institute
    Pasadena, California 91107, United States
  • CNRI-Los Angeles. LLC
    Pico Rivera, California 90660, United States
  • Clinical Innovations, Inc.
    Riverside, California 92647, United States
  • CNRI-San Diego
    San Diego, California 92126, United States
  • UCSD Medical Center
    Sandeigo, California 92103, United States
  • Segal Institute for Clinical Research
    Highlands Ranch, Colorado 80103, United States
  • Comprehensive Neuroscience, Inc.
    Washington, District of Columbia 20016, United States
  • Florida Clinical Research Center
    Bradenton, Florida 34208, United States
  • Florida Clinical Research Center, LLC
    Fruitland Park, Florida 34731, United States
  • Lake Charles Clinical Trials
    Lake Charles, Louisiana 70601, United States
  • Booker, J. Gary, MD. APMC
    Shreveport, Louisiana 71104, United States
  • Precise Clinical Research
    Flowood, Mississippi 39232, United States
  • St. Charles Psychiatric Associates
    St Charles, Missouri 63301, United States
  • St. Louis Research, Inc.
    St. Louis, Missouri 63118, United States
  • CRI Worldwide
    Willingboro, New Jersey 08046, United States
  • Comprehensive Neuroscience, Inc
    Holliswood, New York 11423, United States
  • Segal Institute for Clinical Research
    Winston-Salem, North Carolina 27104, United States
  • Community Clinical Research
    Austin, Texas 78729, United States
  • Future Search Trials of Neurology
    Austin, Texas 78756, United States
  • Pillar Clinical Research
    Dallas, Texas 75243, United States
  • Vijayawada Institute of Mental Health and Neurosciences
    Vijayawada, Andhra Pradesh 520002, India
  • S.V. Medical College
    Tirupati, Andra Pradesh 517507, India
  • Seth K M School of P G Medicine & Research
    Ahmedabad, Gujarat 380006, India
  • SBKS Medical Institute and Research Centre
    Vadodara, Gujarat 391760, India
  • Justice K.S. Hegde Charitable Hospital
    Mangalore, Karnataka 574160, India
  • JSS Medical College and Hospital
    Mysore, Karnataka 570004, India
  • Shanti Nursing Home
    Aurangabad, Maharastra 431005, India
  • Deenanath Mangeshkar Hospital and Research Centre
    Pune, Maharastra 411004, India
  • Mahatma Gandhi Institute of Medical Sciences
    Sewagram, Maharastra 442102, India
  • Madras Medical College & Government General Hospital
    Chennai, TamilNadu 600003, India
  • Spitalul Clinic Judetean de Urgenta Arad
    Str. Octavian Goga nr. 17, Arad 310022, Romania
  • Spitalul de Psihiatrie Titan "Dr. Constantin Gorgos"
    Bdul Nicolae Grigorescu nr. 41, Bucuresti 030440, Romania
  • Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia
    Sos. Berceni nr. 10-12, Bucuresti 041914, Romania
  • Spitalul Judetean Arges
    Str. Negru Voda nr. 53, Pitesti 110069, Romania
  • Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia
    Bucuresti, Romania
  • Spitalul Clinic de Neurologie si Psihiatrie Oradea
    Oradea, Romania
  • SEI of H.P. Educat. Northern SMU
    Arkhangelsk, 163060, Russian Federation
  • St. Petersburg SHI Psychiatrical Hosptial #1 n.a. Kaschenko
    Gatchina, 188357, Russian Federation
  • Moscow Scientific Research Institute of Psychiatry
    Moscow, 107076, Russian Federation
  • Institution of RAMS Mental Health Research Center of RAMS
    Moscow, 115522, Russian Federation
  • City Clinical Psichiatric Hospital #1
    Nizhniy Novgorod, 603 155, Russian Federation
  • SHI Samara Psychiatric Hospital
    Samara, 443016, Russian Federation
  • City Psychiatric Hospital #2 of St. Nikolay Chudotvorets
    St. Petersburg, Russian Federation
  • City Psychiatric Hospital #3 of Skvortsov-Stepanov
    St. Petersburg, Russian Federation
  • City Psychiatric Hospital #4
    St. Petersburg, Russian Federation
  • SHI City Psychoneurological Dispensary #7
    St. Petersburg, Russian Federation
  • St. Petersburg GUZ City Psychiatric Hospital #6
    St. Petersburg, Russian Federation
  • Kherson Regional Psychiatric Hospital
    Kherson,vil., Stepanovka 73488, Ukraine
  • RCH n.a.I.I.Mechnikov, Reg.Cent. of Psychosom. Pathology
    Dnipropetrovsk, 49005, Ukraine
  • Chair of Psychiatry and Medical Psychology
    Donetsk, 83008, Ukraine
  • Centre of Novel Treatment and Rehabilitation of Psychotic disorders
    Kyiv, Ukraine
  • Kyiv City Psychoneurological Hospital
    Kyviv, Ukraine
  • Lviv Reg.St.Cl.Psych.Hosp
    Lviv, Ukraine
  • Reg. Psychiatric Hospital
    Odessa, Ukraine
  • Poltava Regional Clinical Psychiatric Hospital,
    Poltava, Ukraine
  • Crimean republican Clinical Psychiatric Hospital
    Simferopol, Ukraine
09

References and documents

Publications

  • Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, Pikalov A, Potkin SG. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013 Apr;145(1-3):101-9. doi: 10.1016/j.schres.2013.01.009. Epub 2013 Feb 13. PubMed 23415311 ↗
  • Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013 Nov;23(11):1373-82. doi: 10.1016/j.euroneuro.2013.08.003. Epub 2013 Aug 27. PubMed 24035633 ↗
  • Loebel AD, Siu CO, Cucchiaro JB, Pikalov AA, Harvey PD. Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. CNS Spectr. 2014 Apr;19(2):197-205. doi: 10.1017/S1092852913000904. Epub 2013 Dec 13. PubMed 24330860 ↗
  • Hopkins SC, Ogirala A, Worden M, Koblan KS. Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS. Clin Drug Investig. 2021 Dec;41(12):1067-1073. doi: 10.1007/s40261-021-01094-7. Epub 2021 Nov 9. PubMed 34751928 ↗
  • Harvey PD, Siu CO, Ogasa M, Loebel A. Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study. Schizophr Res. 2015 Aug;166(1-3):334-8. doi: 10.1016/j.schres.2015.06.008. Epub 2015 Jun 24. PubMed 26117157 ↗
  • Nasrallah HA, Cucchiaro JB, Mao Y, Pikalov AA, Loebel AD. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr. 2015 Apr;20(2):140-7. doi: 10.1017/S1092852914000285. Epub 2014 Jun 23. PubMed 24955752 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2008
First posted
Nov 13, 2008
Start
Oct 2008
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Oct 6, 2011
Last update
Mar 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00790192
Responsible party
Sponsor
First posted
Nov 13, 2008
Start date
Oct 2008
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Oct 6, 2011
Last update
Mar 17, 2016

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion